Cleveland Clinic Unveils AI-Powered Platform to Transform Hypertension Management

Cleveland Clinic has launched a groundbreaking clinical decision support platform that improves hypertension control through precision medication selection and real-time integration into clinical workflows. Developed by Thomas Mroz, MD, and Ghaith Habboub, MD, the technology leverages artificial intelligence to help clinicians identify the most effective antihypertensive therapies for individual patients, directly within the electronic health record (EHR).

“This is a clinician support tool,” said Dr. Mroz. “It’s proven to match the right patient with the right medication to get their blood pressure under control faster and more effectively. In the immediate term, it sits at the right hand of the clinician. But looking ahead, chronic disease management will be increasingly automated.”

The platform is designed to address one of the most persistent challenges in hypertension care: poor control rates. Globally, more than 1.3 billion people suffer from high blood pressure, with control rates in underserved regions often below 40%. By combining AI-driven medication selection with future enhancements in patient education and adherence, the inventors aim to drive control rates significantly higher.

“We’ve always envisioned a comprehensive solution,” Dr. Mroz added. “Medication selection is just one part. We’re also exploring partnerships to integrate reinforcement learning and AI-powered task agent-based education to improve adherence and close the feedback loop.”

The personalized medication recommendation platform is built to integrate directly into clinical workflows, including at Cleveland Clinic. Following validation, full enterprise-wide implementation is planned. Early results show roughly a 20% improvement in hypertension control, with even greater potential when paired with patient education and adherence tools.

Randomized Controlled Trial Launching Soon

To validate the platform’s clinical impact, Cleveland Clinic’s Heart, Vascular & Thoracic Institute will initiate a randomized controlled trial in the coming months. “We’re taking a huge step forward in scaling the technology,” said Thad Meese, MBA, Director, Innovations Development. “The randomized controlled trial isn’t just a milestone; it proves the platform works in real-world settings and gives partners the confidence to expand its use across care environments, laying the foundation for a new standard of care.”

The trial will evaluate the platform’s ability to outperform standard medication selection and demonstrate measurable improvements in time-to-control and overall hypertension outcomes. If successful, the team envisions broader applications across the globe to address hypertension at scale.

Explore the technology. Connect with Innovations.

Cleveland Clinic’s hypertension platform is redefining chronic disease management, bringing precision, speed, and clarity to a space long overdue for transformation. With a randomized controlled trial launching soon, now is the time for industry leaders, researchers, and collaborators to engage.

Learn more about this technology and how it is shaping the future of procedural intelligence and personalized care.

For more information about Cleveland Clinic Innovations' digital health technologies, click here.